TAHO Pharma Business Summary

TAHO Pharmaceuticals (6467.TWO) is a specialty pharmaceutical firm specializing in advanced drug delivery systems (DDS), primarily leveraging its proprietary Transepithelial Delivery System (TDS) platform. The company’s revenue model is built on technology licensing, milestone-based R&D payments, and recurring royalties from global commercialization agreements, supplemented by high-value contract development and manufacturing (CDMO) services for specialized dosage forms. Its core business segments focus on Transdermal DDS (patches) and Transmucosal SSD (oral thin films), with a pipeline targeting Central Nervous System (CNS) disorders, oncology supportive care, and pain management. Within the Taiwanese biotech sector, TAHO competes with Formosa Pharmaceuticals, AnnJi Pharmaceutical, and Sunny Pharmtech; it maintains a competitive advantage through its focus on 505(b)(2) regulatory pathways, transforming existing drugs into non-invasive, high-bioavailability formats that improve patient adherence and clinical outcomes. Founded in 2010, TAHO is led by Chairman and CEO Dr. Shiren (Howard) Lee, who brings over 25 years of experience in pharmaceutical management and healthcare venture capital. Dr. Lee’s professional background includes executive roles at Amphastar and Innopharmax, as well as significant investment experience as a former Partner at the CID Group and Vice President at China Development Industrial Bank (CDIB). The company’s leadership is reinforced by a board of directors with strong ties to Taiwan’s institutional investment landscape, including historical backing from the CID Group and other prominent biotech funds. This executive team provides the strategic and regulatory expertise necessary to advance a portfolio of intellectual property-protected products, such as TAH3311 (Apixaban oral film) and TAH9901 (Methylphenidate patch), toward international market approvals.